These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27154346)

  • 41. Novel Strategies for Efficient Production and Delivery of Live Biotherapeutics and Biotechnological Uses of
    Tavares LM; de Jesus LCL; da Silva TF; Barroso FAL; Batista VL; Coelho-Rocha ND; Azevedo V; Drumond MM; Mancha-Agresti P
    Front Bioeng Biotechnol; 2020; 8():517166. PubMed ID: 33251190
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lactic acid bacteria in the prevention of pneumococcal respiratory infection: future opportunities and challenges.
    Villena J; Oliveira ML; Ferreira PC; Salva S; Alvarez S
    Int Immunopharmacol; 2011 Nov; 11(11):1633-45. PubMed ID: 21708293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lactic acid bacteria as vaccine delivery vehicles.
    Wells JM; Robinson K; Chamberlain LM; Schofield KM; Le Page RW
    Antonie Van Leeuwenhoek; 1996 Oct; 70(2-4):317-30. PubMed ID: 8879413
    [No Abstract]   [Full Text] [Related]  

  • 44. [Progress on the genomics of lactic acid bacteria--a review].
    Wenyi Z; He M; Heping Z
    Wei Sheng Wu Xue Bao; 2008 Sep; 48(9):1270-5. PubMed ID: 19062656
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lactic Acid Bacteria as Delivery Vehicle for Therapeutics Applications.
    Batista VL; da Silva TF; de Jesus LCL; Tapia-Costa AP; Drumond MM; Azevedo V; Mancha-Agresti P
    Methods Mol Biol; 2021; 2183():447-459. PubMed ID: 32959259
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of attenuated bacteria as delivery vectors for DNA vaccines.
    Daudel D; Weidinger G; Spreng S
    Expert Rev Vaccines; 2007 Feb; 6(1):97-110. PubMed ID: 17280482
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical importance of lactic acid bacteria: a short review.
    Kumari A; Catanzaro R; Marotta F
    Acta Biomed; 2011 Dec; 82(3):177-80. PubMed ID: 22783712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recombinant lactic acid bacteria as mucosal biotherapeutic agents.
    Daniel C; Roussel Y; Kleerebezem M; Pot B
    Trends Biotechnol; 2011 Oct; 29(10):499-508. PubMed ID: 21665301
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lactobacilli: vehicles for antigen delivery to the female urogenital tract.
    Rush CM; Hafner LM; Timms P
    Adv Exp Med Biol; 1995; 371B():1547-52. PubMed ID: 7502854
    [No Abstract]   [Full Text] [Related]  

  • 50. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria.
    van Roosmalen ML; Kanninga R; El Khattabi M; Neef J; Audouy S; Bosma T; Kuipers A; Post E; Steen A; Kok J; Buist G; Kuipers OP; Robillard G; Leenhouts K
    Methods; 2006 Feb; 38(2):144-9. PubMed ID: 16414272
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Progress on lactococcus lactis expressing heterologous antigens as live mucosal vaccines].
    Shi D; Song Y; Li YJ
    Wei Sheng Wu Xue Bao; 2006 Aug; 46(4):680-3. PubMed ID: 17037080
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model.
    del Carmen S; Martín Rosique R; Saraiva T; Zurita-Turk M; Miyoshi A; Azevedo V; de Moreno de LeBlanc A; Langella P; Bermúdez-Humarán LG; LeBlanc JG
    J Clin Gastroenterol; 2014; 48 Suppl 1():S12-7. PubMed ID: 25291117
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lactic Acid Bacteria for Delivery of Endogenous or Engineered Therapeutic Molecules.
    Bron PA; Kleerebezem M
    Front Microbiol; 2018; 9():1821. PubMed ID: 30123213
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery.
    Pavot V; Berthet M; Rességuier J; Legaz S; Handké N; Gilbert SC; Paul S; Verrier B
    Nanomedicine (Lond); 2014 Dec; 9(17):2703-18. PubMed ID: 25529572
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adjuvant Strategies for Lactic Acid Bacterial Mucosal Vaccines.
    Vilander AC; Dean GA
    Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31623188
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Live attenuated bacteria as vectors to deliver plasmid DNA vaccines.
    Dietrich G; Spreng S; Favre D; Viret JF; Guzman CA
    Curr Opin Mol Ther; 2003 Feb; 5(1):10-9. PubMed ID: 12669465
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lactobacilli as live vaccine delivery vectors: progress and prospects.
    Seegers JF
    Trends Biotechnol; 2002 Dec; 20(12):508-15. PubMed ID: 12443872
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Virus-like particles for antigen delivery at mucosal surfaces.
    Schneider-Ohrum K; Ross TM
    Curr Top Microbiol Immunol; 2012; 354():53-73. PubMed ID: 21744306
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT
    Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral vaccine delivery by recombinant spore probiotics.
    Cutting SM; Hong HA; Baccigalupi L; Ricca E
    Int Rev Immunol; 2009; 28(6):487-505. PubMed ID: 19954360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.